Compare iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ Inv Grade Corporate Bond ETF vs Zimmer Biomet Holdings Inc — how do they compare? iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $106.78, while Zimmer Biomet Holdings Inc trades at $99.52 (market cap $18.67B). The key difference: Zimmer Biomet Holdings Inc pays a 0.98% dividend while iShares iBoxx $ Inv Grade Corporate Bond ETF pays none, and Zimmer Biomet Holdings Inc is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| LQD | ZBH | |
|---|---|---|
52-Week High | $112.91 | $107.71 |
52-Week Low | $105.96 | $79.58 |
Market Cap | — | $18.67B |
Sector | — | Health |
Enterprise Value | — | $25.74B |
Dividend Yield | — | 0.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LQD trades at $106.12 with minimal daily movement (+0.15%). Technical indicators show a bearish bias with moving averages signaling sell pressure, though oscillators remain neutral. The ETF maintains consistent dividend distributions, with recent payouts ranging from $0.38 to $0.46 per share. Market focus remains on inflation data and Federal Reserve policy amid ongoing Middle East tensions affecting bond yields.
Investment-grade corporate bond ETFs face headwinds from rising Treasury yields and inflation concerns. LQD's stability in dividend payments provides income appeal, but technical weakness suggests cautious near-term positioning. Key risks include interest rate sensitivity and geopolitical volatility impacting fixed income markets.
Zimmer Biomet (ZBH) trades at $97.9, up 0.12% on the day, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, supported by hips, specialty businesses, and technology. Key financials show a P/E of 23.6 and net income margin of 9.48%, while cash flow from operations improved to $1.70B in 2025.
The outlook is positive, with a consensus price target of $103.56 offering ~6% upside. Risks include competitive pressures and margin volatility, but consistent earnings beats and institutional accumulation support a constructive view for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
